Therapeutic Immune Manipulation
Next-generation immunotherapy exploits diverse immune populations to address the challenges that CAR T-cell therapy faces. The post Therapeutic Immune Manipulation appeared first on GEN - Genetic Engineering and Biotechnology News .
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized immunotherapy, with seven blood cancer therapies approved by the Alliance for Cancer Gene Therapy. However, solid tumors and side effects like cytokine release syndrome and neurotoxicity limit its effectiveness. BiTE technology, developed over 30 years, brings T cells to tumor cells by binding both CD3 on T cells and antigens on tumors.
This allows T-cell-mediated killing without autologous cell collection and manufacturing. Amgen is exploring BiTE's potential for early-stage small cell lung cancer treatment and combination with other mechanisms. AlloNK, a lead molecule from Artiva Biotherapeutics, combines high-affinity NK cells with Rituxan to target B cells.
This approach avoids T-cell expansion side effects while requiring a scalable manufacturing process.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
